A Landscape of Artificial Intelligence (AI) In Pharmaceutical R&D

Where you find opportunities to grow

* Can't find your brand, product, service? Join BPT Marketplace

Machine Learning


[Interview] Expediting Drug Discovery Through Advanced Machine Learning

   by Andrii Buvailo    255
[Interview] Expediting Drug Discovery Through Advanced Machine Learning

The application of next-generation data analytics tools, powered by machine learning and artificial intelligence (AI) components, has become a long-term strategic priority for most companies in the pharmaceutical and biotech industries. However, such systems have to make sure the organisational data is findable, accessible, interoperable, and reusable across different sub-systems, applications, departments, teams, and even companies. 

Aigenpulse, a technology company at the forefront of data management and analytics in the Life Science industry, has built a portfolio of tools for working with organisational research data at scale and accelerating the discovery and development of better targets and candidates using advanced machine learning technologies.

Aigenpulse launches data analysis suite to automate flow cytometry

   by Aigenpulse    479
Aigenpulse launches data analysis suite to automate flow cytometry

11th September 2020: Life science and data technology innovator, Aigenpulse, is launching its CytoML Experiment Suite – an automated, end-to-end, machine learning solution specifically aimed at streamlining and automating cytometry analysis at scale and replacing manual gating processes. With it, users will benefit from a single point-of-truth about all cytometry data across any organisation.

Aigenpulse introduces novel data intelligence platform to life science markets

   by Alice Chamberlain    219

Life science and data technology innovator, Aigenpulse, is introducing a new state of-the-art data intelligence platform which is designed to expedite the drug discovery and development process. The Aigenpulse platform harnesses the latest artificial intelligence and machine learning tools to deliver advanced analytics to underpin scientific decision making.

OKRA smashes target of 2 million validated predictions for big Pharma, 6 months early

   by Marina Gonzalo    296
OKRA smashes target of 2 million validated predictions for big Pharma, 6 months early

Cambridge, UK, 19 June 2020 - OKRA, a leading provider of Artificial Intelligence (AI) driven analytics for Life Sciences, today hit an important milestone, delivering 2 million validated predictions so far in 2020, smashing through its yearly target in just half the expected time. This underscores OKRA’s achievements in empowering the pharmaceutical industry with explainable, real-time AI solutions.